Statins - A cure-all for the brain?

Nature Reviews Neuroscience

Volumn 6, Issue 4, 2005, Pages 325-331

  Menge, Til ^a   Hartung, Hans Peter ^b   Stüve, Olaf ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALIA;

EID: 16344387885     PISSN: 1471003X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrn1652     Document Type: Review

References (69)

1. LaRosa, J. C., He, J. & Vupputuri, S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282, 2340-2346 (1999).
2. Ballantyne, C. M. et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163, 553-564 (2003).
3. Graham, D. J. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585-2590 (2004).
4. Ford, E. S., Mokdad, A. H., Giles, W. H. & Mensah, G. A. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 107, 2185-2189 (2003).
5. Kobashigawa, J. A. et al. Effect of pravastatin on outcomes after cardiac transplantation. W. Engl. J. Med. 333, 621-627 (1995).
6. Willerson, J. T. & Ridker, P. M. Inflammation as a cardiovascular risk factor. Circulation 109, II2-II10 (2004).
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
8. Topol, E. J. Intensive statin therapy - a sea change in cardiovascular prevention. N. Engl. J. Med. 350, 1562-1564 (2004).
9. Stanislaus, R., Pahan, K., Singh, A. K. & Singh, I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 269, 71-74 (1999).
10. Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84 (2002).
11. Aktas, O. et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197, 725-733 (2003).
12. Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 7, 687-692 (2001).
13. Romano, M. et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. 80, 1095-1100 (2000).
14. Bellosta, S. et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 18, 1671-1678 (1998).
15. Neuhaus, O. et al. Statins as immunomodulators: comparison with interferon-β 1b in MS. Neurology 59, 990-997 (2002).
16. Kieseier, B. C., Archelos, J. J. & Hartung, H. P. Different effects of simvastatin and interferon β on the proteolytic activity of matrix metalloproteinases. Arch. Neurol. 61, 929-932 (2004).
17. Sena, A., Pedrosa, R. & Graca, M. M. Therapeutic potential of lovastatin in multiple sclerosis. J. Neurol. 250, 754-755 (2003).
18. Vollmer, T. et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363, 1607-1608 (2004).
19. Wechsler, A. et al. Generation of viable cholesterol-free mice. Science 302, 2087 (2003).
20. Refolo, L. M. et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in atransgenic mouse model. Neurobiol. Dis. 7, 321-331 (2000).
21. Sparks, D. L. et al. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88-94 (1994).
22. Fassbender, K. et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 5856-5861 (2001).
23. Simons, M. et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52, 346-350 (2002).
24. Fassbender, K. et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59, 1257-1258 (2002).
25. Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421 (2000).
26. Kwak, B., Mulhaupt, F., Myit, S. & Mach, F. Statins as a newly recognized type of immunomodulator. Nature Med. 6, 1399-1402 (2000).
27. Yankner, B. A. et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245, 417-420 (1989).
28. Pahan, K., Sheikh, F. G., Namboodiri, A. M. & Singh, I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100, 2671-2679 (1997).
29. Naidu, A., Xu, Q., Catalano, R. & Cordeil, B. Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Res. 958, 100-111 (2002).
30. Gearing, M., Mori, H. & Mirra, S. S. Aβ-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann. Neurol. 39, 395-399 (1996).
31. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. & Drachmen, D. A. Statins and the risk of dementia. Lancet 356, 1627-1631 (2000).
32. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G. & Siegel, G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443 (2000).
33. Rockwood, K. et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59, 223-227 (2002).
34. Yaffe, K., Barrett-Connor, E., Lin, F. & Grady, D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol. 59, 378-384 (2002).
35. Shepherd, J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630 (2002).
36. Li, G. et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63, 1624-1628 (2004).
37. Casserly, I. & Topol, E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363, 1139-1146 (2004).
38. Amarenco, P. & Tonkin, A. M. Statins for stroke prevention: disappointment and hope. Circulation 109, III44-III49 (2004).
39. Collins, R., Armitage, J., Parish, S., Sleight, P. & Peto, R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363, 757-767 (2004).
40. Sever, P. S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003).
41. Briel, M., Studer, M., Glass, T. R. & Bucher, H. C. Effects of Statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. 117, 596-606 (2004).
42. Kastelein, J. J., de Groot, E. & Sankatsing, R. Atherosclerosis measured by B-mode ultrasonography: effect of statin therapy on disease progression. Am. J. Med. 116 (Suppl. 6A), 31S-36S (2004).
43. Ross, R. Atherosclerosis - an inflammatory disease, N. Engl. J. Med. 340, 115-126 (1999).
44. Crisby, M. et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103, 926-933 (2001).
45. Weber, C., Erl, W., Weber, K. S. & Weber, P. C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 30, 1212-1217 (1997).
46. Endres, M. et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 95, 8880-8885 (1998).
47. Ongini, E. et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc. Natl Acad. Sci. USA 101, 8497-8502 (2004).
48. Notarbartolo, A. et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15, 247-251 (1995).
49. Zacco, A. et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J. Neurosci. 23, 11104-11111 (2003).
50. Chen, J. et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann. Neurol. 53, 743-751 (2003).
51. Chopp, M. et al. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke 25, 869-875 (1994).
52. Sterzer, P. et al. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 32, 2817-2820 (2001).
53. Marti-Fabregas, J. et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 35, 1117-1121 (2004).
54. Nissen, S. E. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
55. Amarenco, P. et al. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc. Dis. 16, 389-395 (2003).
56. Hebert, L. E., Scherr P. A., Bienias, J. L., Bennett, D. A. & Evans, D. A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60, 1119-1122 (2003).
57. Haake, M. et al. The German multicenter, randomized, partially blinded, prospective trial of acupuncture for chronic low-back pain: a preliminary report on the rationale and design of the trial. J. Altern. Complement. Med. 9, 763-770 (2003).
58. Smith, D. G. & McBurney, C. R. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). Pharmacoeconomics 21 (Suppl. 1), 13-23 (2003).
59. Divis, D. A. BioWar: 'wild card' patent in Bioshield 2? The Washington Times (1 Sep 2004) 〈http://washingtontimes.com/upi-breaking/20040901- 084333-2886r.htm〉.
60. Vancura, A., Sessler, A., Leichus, B. & Kuret, J. A prenylation motif is required for plasma membrane localization and biochemical function of casein kinase I in budding yeast. J. Biol. Chem. 269, 19271-19278 (1994).
61. Wozniak, M. A., Kwong, L., Chodniewicz, D., Klemke, R. L. & Keely, P. J. R-Ras controls membrane protrusion and cell migration through the spatial regulation of Rac and Rho. Mol. Biol. Cell 16, 84-96 (2005).
62. Mundy, G. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946-1949 (1999).
63. Singh, R. et al. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J. Clin. Invest. 103, 1561-1570 (1999).
64. Laufs, U. et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest. 106, 15-24 (2000).
65. Inoue, I. et al. Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB. Biochem. Biophys. Res. Commun. 290, 131-139 (2002).
66. Baetta, R. et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol. Res. 36, 115-121 (1997).
67. Hernandez-Perera, O. et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101, 2711-2719 (1998).
68. Lawman, S., Mauri, C., Jury, E. C., Cook, H. T. & Ehrenstein, M. R. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J. Immunol. 173, 7641-7646 (2004).
69. Neuhaus, O., Stüve, O., Zamvil, S. S. & Hartung, H. P. Are statins a treatment option for multiple sclerosis? Lancet Neurol. 3, 369-371 (2004).